TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29932516

Group type: EXPERIMENTAL
Intervention: BWC combined with CBT-D
Number of subjects: 76

Group type: COMPARATOR
Intervention: CBT-D
Number of subjects: 76

Group type: COMPARATOR
Intervention: BWC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All groups (BWC, CBT-D, BWC combined with CBT-D)
Number of subjects: 76
Study: 26141262

Group type: EXPERIMENTAL
Intervention: SCIT (Alutard SQ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open control group
Number of subjects: 24
Study: 24281361

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) plus Treatment as Usual (TAU)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 82
Study: 23363920

Group type: EXPERIMENTAL
Intervention: Psychosocial services provided by social workers
Number of subjects: 300
Study: 19756028

Group type: EXPERIMENTAL
Intervention: Nut consumption (rarely/never, <1, 1, 2-4, 5-6, 7+ servings per week)
Number of subjects: 20224

Group type: COMPARATOR
Intervention: Nut consumption
Number of subjects: 20224
Study: 18251623

Group type: EXPERIMENTAL
Intervention: Ziprasidone (mean daily dose 84.1 mg/day, SD = 54.8; range, 40-200)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16825332

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg for women; 200 mg for men)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate and resistance exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 79
Study: 14657829

Group type: EXPERIMENTAL
Intervention: Intramuscular iron
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral iron (3 months)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 5
Study: 11016326

Group type: EXPERIMENTAL
Intervention: 1000 U AT concentrate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Additional heparin
Number of subjects: 85
Study: 9001875

Group type: EXPERIMENTAL
Intervention: Cefonicid 1 g given by intravenous infusion 30 minutes before the operation
Number of subjects: 35
Study: 1333962

Group type: EXPERIMENTAL
Intervention: Atropine blockade
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 6
Study: 4017884

Group type: EXPERIMENTAL
Intervention: Fibrin seal used intraoperatively in 19 patients
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard care without fibrin seal
Number of subjects: 417
Study: 30231106

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 266 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no liposomal bupivacaine)
Number of subjects: 69
Study: 27210851

Group type: COMPARATOR
Intervention: Strengthening training (ST)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Strengthening training + whole body vibration training (ST + WBV)
Number of subjects: 28
Study: 24886402

Group type: EXPERIMENTAL
Intervention: Day Hospital Mentalization-Based Treatment (MBT-DH)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 2
Study: 23246445

Group type: EXPERIMENTAL
Intervention: CWI at 8°C
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CWI at 15°C
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CWI at 8°C and CWI at 15°C
Number of subjects: 9
Study: 19853892

Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard hospitalization
Number of subjects: 132
Study: 18466359

Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study: 15911727

Group type: EXPERIMENTAL
Intervention: NNT of 50
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: NNT of 1600
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Avoiding lethal disease
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Preventing stroke
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Preventing myocardial infarction
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Preventing hip fracture
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Treatment costs of $37
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Treatment costs of $68
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Treatment costs of $162
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Treatment costs of $589
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Interpretation of NNT
Number of subjects: 1201
Study: 12822091

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bedside teaching
Number of subjects: 16
Study: 10697395

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (streptokinase or tissue-type plasminogen activator)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (28 healthy persons)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patients with anterior AMI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patients with inferior AMI
Number of subjects: 94
Study: 8738616

Group type: EXPERIMENTAL
Intervention: Microscopic vasovasostomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macroscopic vasovasal anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 1680422

Group type: EXPERIMENTAL
Intervention: CCPD
Number of subjects: 56

Group type: COMPARATOR
Intervention: CAPD-Y
Number of subjects: 56
Study: 6110093

Group type: EXPERIMENTAL
Intervention: LM24056 at 100 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LM24056 at 200 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LM24056 at 300 mg
Number of subjects: 23
Study: 31984963

Group type: EXPERIMENTAL
Intervention: Artmaking with fluid materials (e.g., finger paints)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artmaking with less fluid materials (e.g., gouache paint with a brush)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Music listening before each art making session
Number of subjects: 0
Study: 31053990

Group type: EXPERIMENTAL
Intervention: Parent-mediated home-based intervention focusing on joint attention, imitation, social and adaptive skills, delivered in five outpatient sessions over 12 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control group (details not specified).
Number of subjects: 50
Study: 27943042

Group type: EXPERIMENTAL
Intervention: LAAFV (Left Atrial Appendage Flow Velocity)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LAAFV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Follow-up after catheter ablation
Number of subjects: 120
Study: 27400910

Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer (BRBC) program
Number of subjects: 204
Study: 25213048

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate-vilanterol 100-25 mcg
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 21918905

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg per day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19576676

Group type: EXPERIMENTAL
Intervention: Alternating rescuers every 1 minute
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alternating rescuers every 2 minutes
Number of subjects: 80
Study: 18156033

Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol maintenance and reliever therapy
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Fixed-dose budesonide plus formoterol
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Fixed-dose fluticasone plus salmeterol
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Adjustable regimen of budesonide plus formoterol
Number of subjects: 2250
Study: 15167427

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 21
Study: 12575620

Group type: EXPERIMENTAL
Intervention: Quantitative IgE measurement using the CAP-system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative IgE measurement by intensity of fluorescence
Number of subjects: 0
Study: 9700784

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (without external nasal dilator strip)
Number of subjects: 17
Study: 7867676

Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2744909

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 400 mg/day for 13 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Phenytoin 300 mg/day for 13 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 105970

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (200 mg qds)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31773821

Group type: EXPERIMENTAL
Intervention: Amputated limb quadriceps
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maximal voluntary torque (MVT) in amputated limb
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rate of torque development (RTD) in amputated limb
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Neural activation in amputated limb
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Muscle thickness in amputated limb
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intrinsic contractile properties in amputated limb
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control limb (intact limb)
Number of subjects: 9
Study: 31331772

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mathematical models assuming no latency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mathematical models including reactivation of latent infection
Number of subjects: 0
Study: 28673765

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no adhesive)
Number of subjects: 128
Study: 25578128

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Optical rhinometry (ORM)
Number of subjects: 25
Study: 23969483

Group type: COMPARATOR
Intervention: Full guided parent-delivered CBT (four face-to-face and four telephone sessions)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Brief guided parent-delivered CBT (two face-to-face and two telephone sessions)
Number of subjects: 194
Study: 21625085

Group type: EXPERIMENTAL
Intervention: Nocturnal home HD (5-6 times per week)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional HD (3 times per week)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Nocturnal home HD (6 times per week)
Number of subjects: 139
Study: 19333154

Group type: EXPERIMENTAL
Intervention: 8% lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 24
Study: 17007869

Group type: EXPERIMENTAL
Intervention: Children aged 6 years and adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All age groups (including children aged 4 years)
Number of subjects: 0
Study: 14998615

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 5491

Group type: EXPERIMENTAL
Intervention: Diabetic men
Number of subjects: 5491

Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 5491

Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 5491
Study: 11741361

Group type: EXPERIMENTAL
Intervention: Early invasive strategy with coronary angiography/revascularization within 7 days
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Non-invasive strategy with coronary procedures only when symptoms or severe ischaemia recurred
Number of subjects: 2457
Study: 9819646

Group type: EXPERIMENTAL
Intervention: FLAIR sequence at 0.5 Tesla
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MRA (3D-TOF) at 0.5 Tesla
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (10 patients without SAH)
Number of subjects: 19
Study: 8030597

Group type: EXPERIMENTAL
Intervention: Taurine 10.8 mg/kg ideal body weight (group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Taurine 50 mg/kg ideal body weight (group 3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No taurine (control group)
Number of subjects: 20
Study: 2729161

Group type: EXPERIMENTAL
Intervention: PPBG less than 13 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPBG greater than 13 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusion of participants with PPBG greater than 13 mmol/L
Number of subjects: 0
Study: 31927654

Group type: EXPERIMENTAL
Intervention: Streamlined prevention and early intervention (SPEI)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study: 29028128

Group type: EXPERIMENTAL
Intervention: MRI proton density fat fraction (PDFF)
Number of subjects: 169
Study: 27777795

Group type: EXPERIMENTAL
Intervention: P-SIT (sprint-interval training with passive recovery)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ET (endurance training)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: A-SIT (sprint-interval training with active recovery)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CON (nonexercise control condition)
Number of subjects: 62
Study: 25697600

Group type: EXPERIMENTAL
Intervention: Glycaemic load counting (GLC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbohydrate counting (CC)
Number of subjects: 9
Study: 23698160

Group type: EXPERIMENTAL
Intervention: Folate enriched diet (200 μg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5-MTHF (200 μg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Folic acid (200 μg)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 20647200

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily for 52 weeks
Number of subjects: 3182

Group type: EXPERIMENTAL
Intervention: Lorcaserin continued in year 2
Number of subjects: 3182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3182

Group type: COMPARATOR
Intervention: Placebo continued in year 2
Number of subjects: 3182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3182

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 3182
Study: 18973730

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15998758

Group type: EXPERIMENTAL
Intervention: Lower-than-usual target blood pressure
Number of subjects: 0
Study: 12517200

Group type: EXPERIMENTAL
Intervention: Use of reliever medications
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Use of controller medications
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Asthma control adequacy
Number of subjects: 638
Study: 10574652

Group type: COMPARATOR
Intervention: Butter (B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interesterified mixture (IM) of butter, medium-chain triacylglycerol (MCT), and safflower oils
Number of subjects: 30
Study: 10160460

Group type: EXPERIMENTAL
Intervention: Esophageal Detector Device (EDD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Airway managers (control)
Number of subjects: 5
Study: 1715450

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and triamterene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa or placebo
Number of subjects: 0
Study: 7137522

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 100 mg sustained-release preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 50 mg combined with antihistamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydroergotamine (DHE) 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPA (100 mg) and combined preparation containing PPA (50 mg) taken twice a day
Number of subjects: 0
Study: 30527555

Group type: EXPERIMENTAL
Intervention: Guardix® (liquid-based hyaluronic acid and carboxymethyl cellulose solution)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Seprafilm® (sodium hyaluronate-based bioresorbable membrane)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (no anti-adhesive)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Seprafilm® vs Control
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Guardix® vs Seprafilm®
Number of subjects: 488
Study: 28599762

Group type: EXPERIMENTAL
Intervention: Integrated Co-teaching (ICT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Teaching (CT)
Number of subjects: 100
Study: 27577112

Group type: EXPERIMENTAL
Intervention: SQ-LNS (20 g sachet per day during pregnancy and first 6 months of lactation)
Number of subjects: 2189

Group type: COMPARATOR
Intervention: Control groups (multiple micronutrients during pregnancy and lactation or iron and folic acid during pregnancy and calcium during lactation)
Number of subjects: 2189
Study: 25188375

Group type: EXPERIMENTAL
Intervention: Standard bolus delivered with meal (n=51)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Standard bolus delivered 15 min prior to meal (n=40)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Over-bolus of 30% delivered with meal (n=40)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Bolus purposely omitted (n=46)
Number of subjects: 53
Study: 23023460

Group type: EXPERIMENTAL
Intervention: Pediatrician in triage (PIT)
Number of subjects: 6579

Group type: COMPARATOR
Intervention: Conventional registered nurse‐driven triage (control)
Number of subjects: 6579
Study: 19462490

Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake
Number of subjects: 4919

Group type: EXPERIMENTAL
Intervention: Increased dietary potassium intake
Number of subjects: 4919
Study: 17098771

Group type: EXPERIMENTAL
Intervention: Computer-assisted self-interview (CASI)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Face-to-face interview (FTFI)
Number of subjects: 611
Study: 16269298

Group type: EXPERIMENTAL
Intervention: Bariatric operation (not specified dosage or duration)
Number of subjects: 248
Study: 12162474

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg x 3, q4-6h)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 10786514

Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no weight management program)
Number of subjects: 114
Study: 8522738

Group type: EXPERIMENTAL
Intervention: Flexor carpi ulnaris to extensor digitorum communis tendon transfer
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (10 volunteers)
Number of subjects: 6
Study: 1972947

Group type: EXPERIMENTAL
Intervention: 2% calcium mupirocin ointment after tincture of iodine
Number of subjects: 218

Group type: COMPARATOR
Intervention: tincture of iodine (control)
Number of subjects: 218
Study: 7439516

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Half dose combination of slow-release aminophylline and salbutamol
Number of subjects: 16
Study: 31196470

Group type: EXPERIMENTAL
Intervention: Port site resection (PSR)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No port site resection (No-PSR)
Number of subjects: 123
Study: 29798201

Group type: EXPERIMENTAL
Intervention: Binglianqingye Spray
Number of subjects: 360

Group type: COMPARATOR
Intervention: Jinsangzi Tablet
Number of subjects: 360

Group type: COMPARATOR
Intervention: Jinhoujian Spray
Number of subjects: 360
Study: 27108410

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review (PMC) at study start (T-0) and after 28 weeks (T-28)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review (PMC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group received only a PMC at T-28
Number of subjects: 450
Study: 24354731

Group type: EXPERIMENTAL
Intervention: Surgically modified vulvas
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nonmodified vulvas
Number of subjects: 97

Group type: COMPARATOR
Intervention: No images (Control)
Number of subjects: 97
Study: 22781864

Group type: EXPERIMENTAL
Intervention: High life stress and DRD4 7 + R allele
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Life Stress × DRD4 Status interaction
Number of subjects: 399
Study: 21071989

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 284
Study: 18421919

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBCT) for 120-180 seconds at temperatures between -110°C and -160°C, 15 treatments over 3 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard psychopharmacological treatment (not specified)
Number of subjects: 60
Study: 15206496

Group type: COMPARATOR
Intervention: Enalapril 10 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Losartan 50 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg/day enalapril and 50 mg/day losartan)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Double-dose monotherapy (20 mg/day enalapril or 100 mg/day losartan)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy (enalapril and losartan)
Number of subjects: 22